Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.

One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.

[7][4][5] Idarucizumab is a non-competitive inhibitor that forms complexes with dabigatran to counteract its anticoagulant effect within minutes of administration.

[9] A major adverse effect is thromboembolism resulting in stroke, pulmonary embolism, deep vein thrombosis and heart attack.

Idarucizumab, if indicated, may be taken during pregnancy, due to the benefits it provides to the patient compared to the unclear risk to the fetus.